Merck Stock Is Outperforming In A Volatile Market. This Trade Puts An 11% Return In Sight.

Core Viewpoint - Merck is positioned well during market corrections, focusing on expanding its cancer treatment portfolio and offering investment opportunities through options strategies that could yield an annualized return of 11.16% [1][3][4]. Investment Strategy - Investors can either buy Merck stock directly or utilize options, such as a cash-secured put option, to potentially acquire shares at a discount [2]. - A suggested strategy involves selling a put option with a strike price of 110, which could generate approximately $830 in premium, leading to a potential annualized return of 11.16% if the stock remains above the strike price [3][4]. Risk and Exposure - Selling the put option exposes investors to a scenario where they may have to purchase 100 shares at 110 if the stock price falls below this level by expiration [4]. - The current delta of the 110 strike put is 32, indicating an exposure equivalent to owning 32 shares of Merck, with a 68% chance of the option expiring worthless [5]. Company Overview - Merck generates over $65 billion in annual revenue, with key products like Keytruda and Gardasil significantly contributing to its growth [6]. - The company has a strong market position, holding a Composite Rating of 96 out of 99, and ranks second in its industry group [7].